Please login to the form below

Not currently logged in
Email:
Password:

NIHR appoints Simon Denegri to lead public engagement in research

Former AMRC CEO joins as national director for public participation and engagement in research

The UK's National Institute for Health Research (NIHR) has appointed Simon Denegri as the Institute's national director for public participation and engagement in research.

In his new position Denegri will be tasked with encouraging more people to take part in health and social care research in the UK.

This will include giving patients the right information and support to be able to talk to NHS staff about ongoing research into their condition.

Denegri, who is also currently chair of the NIHR's Involve programme, will work closely with NHS organisations, Public Health England, Healthwatch, patient groups and other stakeholders in this new role.

His previous roles include serving as CEO of Ovarian Cancer Action for six months during 2011 and CEO of the Association of Medical Research Charities (AMRC) from 2006 until 2011.

Prior to his role at the AMRC, Denegri was director of corporate communications at the Royal College of Physicians of London from 2003.

23rd March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Litmus MME

LITMUS places the development of strong physician relationships at the centre of every program and has established a new standard...

Latest intelligence

blog-icon_build_your_argumentation.png
Build your e-detailing argumentation
We’ve written a number of posts recently giving insights into the Anthill method for structuring e-detailing & CLM presentations. To help you overview, we’ve put these argumentation posts together....
Growing influence of pharmacists in the sale of Rx and OTC medicines
Find out how the changes within pharmacy have affected their influence over the sales of RX and OTC medicines in this whitepaper....
Drivers of 2014′s Soaring Drug Approvals
The FDA & EMA approved a chart-topping number of new drugs in 2014. Read more in our White Paper about the responsibility this growing approval success will put on future...